Table of contents
- Trial overview
- COPD and heart failure study
- COPD health status and treatment comparison studies
- Asthma, adherence, and control study
- What the study endpoints mean
- Who the studies target
Trial overview
The trial data show that Umeclidinium Bromide is being studied in Phase 3 interventional trials, mostly in people with chronic obstructive pulmonary disease (COPD). In the listed studies, it appears as part of combination inhaled treatments and as one of several treatment options being compared. The main focus is not on the drug itself, but on patient outcomes such as health status, clinical control, exercise measures, and treatment adherence.[1][2][3]
COPD and heart failure study
One authorised Phase 3 study is looking at patients with COPD and heart failure, with left ventricular ejection fraction between 35% and 50%. This means the study includes people whose heart pumping function is reduced but not absent. The study compares dual bronchodilation with umeclidinium/vilanterol against placebo and other inhaled treatments, and it plans to enroll 60 people.[1]
The main outcomes in this study are exercise-related heart measures. Researchers want to measure the baseline-corrected time-velocity integral, which is a direct surrogate of stroke volume, during peak exercise, and also the maximal oxygen pulse on a cycle-ergometer cardiopulmonary exercise test. In simple terms, the study is checking whether treatment changes how much blood the heart pumps during exercise and how the body uses oxygen.[1]
COPD health status and treatment comparison studies
Two completed Phase 3 studies focus on COPD treatment choices in larger patient groups. The TRACkER trial enrolled 316 people and compared triple therapy with LABA/LAMA treatment groups. Its main endpoint was the difference in the proportion of patients who had a clinically relevant improvement in health status, measured by the Clinical COPD Questionnaire (CCQ) after 26 weeks.[3]
In this trial, triple therapy means three inhaled medicines used together, while LABA/LAMA means a long-acting beta agonist plus a long-acting muscarinic antagonist. The study included symptomatic COPD patients who had not used inhaled corticosteroids before and who also had asthma-like features according to GOLD 2019, plus blood eosinophil counts of at least 100 cells per microliter. This tells us the researchers were looking at a specific COPD subgroup that may respond differently to inhaled treatment choices.[3]
The ANTES B+ study was another completed Phase 3 trial with 1,028 patients. It compared triple therapy with LABA-LAMA combination treatment in high-risk GOLD B COPD patients, and it looked at whether patients stayed persistently controlled at all study visits across months 3, 6, 9, and 12. The study used a validated composite endpoint called clinical control, which combines stability and impact.[4]
In this study, the main question was whether Trelegy® worked better than LABA-LAMA treatment for keeping COPD under control over time. Umeclidinium Bromide appears in the list of treatments being compared, which shows that it is part of the inhaled treatment strategies studied in COPD care research.[4]
Asthma, adherence, and control study
One completed Phase 3 study, SECURE, enrolled 130 people with asthma. The study compared monthly treatment delivery by a nurse using a pre-filled syringe with self-administered treatment using an auto-injector pen. Although the trial title is about mepolizumab devices, the source data also lists Incruse Ellipta among the inhaled treatments included in the study data set.[2]
The main outcomes were treatment compliance and asthma control after 6 months. Compliance was checked using pharmacy accountability and monthly patient diaries, and asthma control was measured with the ACT score, which stands for Asthma Control Test. This means the study was focused on whether patients used treatment as planned and whether their asthma stayed controlled.[2]
What the study endpoints mean
A primary outcome is the main result a trial is designed to measure. In these trials, the primary outcomes include exercise heart measures, health status improvement on the CCQ, persistent clinical control, treatment compliance, and asthma control. These outcomes help researchers judge whether a treatment is useful for real patient care, not just whether it can be given in a study.[1][2][3][4]
A composite endpoint combines more than one result into one main study measure. This is used in the ANTES B+ study for clinical control, where patients needed to meet criteria at several study visits to be counted as controlled. This kind of endpoint gives a fuller picture of long-term disease control.[4]
In the TRACkER study, the CCQ was used to measure whether health status improved by at least 0.4 points. A change like this is treated as clinically relevant, meaning it is large enough to matter in everyday life.[3]
Who the studies target
The trials mainly target adults with COPD, including people with symptoms, asthma-like features, or high-risk disease patterns. One study also includes patients with COPD and heart failure, while another study includes people with asthma. The trial data therefore show that Umeclidinium Bromide is being studied in different patient groups where inhaled treatment choices are important.[1][2][3][4]
Across the listed studies, the research is focused on practical questions: does the treatment improve symptoms, help patients stay controlled, and support better daily function or exercise performance? Because the studies are Phase 3, they are designed to provide stronger evidence in larger groups of patients before broader use decisions are made.[1][3][4]
